Prasugrel

Nature Reviews Drug Discovery

Volumn 8, Issue 6, 2009, Pages 449-450

  Huber, Kurt ^a   Yasothan, Uma ^b   Hamad, Bashar ^b   Kirkpatrick, Peter ^c  

^a WILHELMINEN HOSPITAL   (Austria)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; EFIENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LOADING DRUG DOSE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

DOUBLE-BLIND METHOD; DRUG DESIGN; DRUG INDUSTRY; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, PURINERGIC P2; THIOPHENES;

EID: 66749180425     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2899     Document Type: Article

References (18)

1. Bhatt, D. L. & Topol, E. J. Scientific and therapeutic advances in antiplatelet therapy. Nature Rev. Drug Discov. 2, 15-28 (2003).
2. Raju, N. C. et al. Platelet ADP-receptor antagonists for cardiovascular disease: Past, present and future. Nature Clin. Pract. Cardiovasc. Med. 5, 766-780 (2008).
3. Sugidachi, A. et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br. J. Pharmacol. 129, 1439-1446 (2000).
4. 12 receptor antagonist activity. Semin. Thromb. Hemost. 31, 184-194 (2005).
5. Jernberg T. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J. 27, 1166-1173 (2006).
6. Brandt, J. T. et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. 153, 66.e9-66.e16 (2007).
7. Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
8. European Medicines Agency (EMEA). European Public Assessment Report - Efient. EMEA website [online], http://www.emea.europa.eu/ humandocs/PDFs/EPAR/Efient/H-984-PI-en.pdf (2009).
9. Siller-Matula, J. et al. Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance. Thromb. Haemost. 97 385-393 (2007).
10. Collet, J. P. et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 373, 309-317 (2009).
11. Simon, T. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
12. Mega, J. L. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl J. Med. 360, 354-362 (2009).
13. Ho, P. M. et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301, 937-944 (2009).
14. Lau, W. C. & Gurbel, P. A. Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. Pharm. Res. 23, 2691-2708 (2006).
15. Farid, N. A. et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab. Dispos. 35, 1096-1104 (2007).
16. Antman, E. M. et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A TRITON-TIMI 38 (Trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - thrombolysis in myocardial infarction) analysis. J. Am. Coll. Cardiol. 51, 2028-2033 (2008).
17. IMS MIDAS (2008).
18. Arnold, C. J. et al. Credit Suisse Equity Research Report (Credit Suisse Securities LLC, 31 Mar 2009).